Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21025RF" target="_blank" >RIV/61988987:17110/20:A21025RF - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/20:E0108506

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.2736" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.2736</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/hon.2736" target="_blank" >10.1002/hon.2736</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort

Popis výsledku v původním jazyce

Multiple myeloma (MM) is the second most common blood cancer caused by the uncontrolled proliferation of clonal plasma cells. Despite recent advances in treatment, a majority of patients eventually relapse and die because of progressive disease (PD). Thus, the development of modern molecules with novel mechanisms of action is needed. The overexpression of antiapoptotic proteins (ie, Bcl‐2, Bcl‐XL, Mcl‐1) represents one of the hallmarks of cancer that favors tumor cell survival. It has been demonstrated that a subset of MM is Bcl‐2 dependent. These are especially those harboring the t(11;14)—molecular subgroup which is associated with a high expression of Bcl‐2 and a low expression of Bcl‐XL and Mcl‐1.1, 2 The presence of translocation t(11;14) is present in 15%‐20% of newly diagnosed MM3 and even up in 50% of primary plasma cell leukemia.4

Název v anglickém jazyce

Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort

Popis výsledku anglicky

Multiple myeloma (MM) is the second most common blood cancer caused by the uncontrolled proliferation of clonal plasma cells. Despite recent advances in treatment, a majority of patients eventually relapse and die because of progressive disease (PD). Thus, the development of modern molecules with novel mechanisms of action is needed. The overexpression of antiapoptotic proteins (ie, Bcl‐2, Bcl‐XL, Mcl‐1) represents one of the hallmarks of cancer that favors tumor cell survival. It has been demonstrated that a subset of MM is Bcl‐2 dependent. These are especially those harboring the t(11;14)—molecular subgroup which is associated with a high expression of Bcl‐2 and a low expression of Bcl‐XL and Mcl‐1.1, 2 The presence of translocation t(11;14) is present in 15%‐20% of newly diagnosed MM3 and even up in 50% of primary plasma cell leukemia.4

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

HEMATOLOGICAL ONCOLOGY

ISSN

0278-0232

e-ISSN

1099-1069

Svazek periodika

38

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

3

Strana od-do

412-414

Kód UT WoS článku

000527833100001

EID výsledku v databázi Scopus

—